Trial Profile
A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Capsules for Inhalation in Healthy Subjects and Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs CCI 15106 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 11 Aug 2017 New trial record